Syndax Pharmaceuticals In... (SNDX)
| Bid | 11.87 |
| Market Cap | 1.12B |
| Revenue (ttm) | 23.68M |
| Net Income (ttm) | -318.76M |
| EPS (ttm) | -3.72 |
| PE Ratio (ttm) | -3.49 |
| Forward PE | -4.57 |
| Analyst | Buy |
| Ask | 14.08 |
| Volume | 1,076,495 |
| Avg. Volume (20D) | 2,177,332 |
| Open | 13.35 |
| Previous Close | 12.92 |
| Day's Range | 12.80 - 13.41 |
| 52-Week Range | 9.66 - 25.07 |
| Beta | 1.28 |
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...
Analyst Forecast
According to 10 analyst ratings, the average rating for SNDX stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 184.72% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call TranscriptSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gal...
